Bhaskar Chaudhuri

Dr. Bhaskar Chaudhuri has been an Operating Partner at Frazier Healthcare since 2011, focusing on investments in later-stage companies and in international opportunities. Prior to joining Frazier, he was president of Valeant Pharmaceuticals (currently Bausch Health), where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he was President and CEO. Dow focused on dermatology drug development and commercialization and was the source of multiple approved products. Before Dow, Dr. Chaudhuri worked at Mylan Pharmaceuticals in several capacities including EVP of scientific affairs at Mylan subsidiary Bertek Pharmaceuticals, and as general manager of the dermatology division. He also worked at Penederm as VP of R&D. In addition to Sudo, he also serves on the board of Arcutis (NASDAQ: ARQT), Silvergate Pharmaceuticals, and Tarsus (NASDAQ: TARS). He also serves on the advisory board of the Johns Hopkins Berman Institute of Bioethics. He holds a Ph.D. from the University of Louisiana, and an M.S. and a B.S. in Pharmacy from Jadavpur University, India.